Costs associated with febrile neutropenia in the US.

Publication Type:

Journal Article

Source:

PharmacoEconomics, Volume 30, Issue 9, p.809-23 (2012)

Keywords:

Antineoplastic Agents, Bone Marrow, Cohort Studies, Delivery of Health Care, Drug Costs, Economics, Pharmaceutical, Female, Fever, Health Care Costs, Humans, Male, Middle Aged, Neoplasms, NEUTROPENIA, Retrospective Studies, United States

Abstract:

Febrile neutropenia (FN) is a potentially life-threatening condition that may develop in cancer patients treated with myelosuppressive chemotherapy and result in considerable costs. This study was designed to estimate US healthcare utilization and costs in those experiencing FN by location of care, tumour type and mortality.